US 12,070,473 B2
Cancer-killing cells
Alex Blyth, Brighton (GB); and Nico Bruyniks, Brighton (GB)
Assigned to LIFT BIOSCIENCES LTD, Brighton (GB)
Appl. No. 16/759,293
Filed by LIFT BIOSCIENCES LTD, Brighton (GB)
PCT Filed Apr. 24, 2018, PCT No. PCT/GB2018/051073
§ 371(c)(1), (2) Date Apr. 24, 2020,
PCT Pub. No. WO2019/081879, PCT Pub. Date May 2, 2019.
Claims priority of application No. PCT/GB2017/053222 (WO), filed on Oct. 25, 2017.
Prior Publication US 2021/0189340 A1, Jun. 24, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/15 (2015.01); A61K 31/198 (2006.01); A61K 31/202 (2006.01); A61K 31/375 (2006.01); A61K 31/59 (2006.01); A61K 35/28 (2015.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 38/27 (2006.01); A61P 35/00 (2006.01); C12N 5/0787 (2010.01); C12N 5/0789 (2010.01); G01N 33/574 (2006.01); A61K 48/00 (2006.01)
CPC A61K 35/15 (2013.01) [A61K 31/198 (2013.01); A61K 31/202 (2013.01); A61K 31/375 (2013.01); A61K 31/59 (2013.01); A61K 35/28 (2013.01); A61K 38/193 (2013.01); A61K 38/20 (2013.01); A61K 38/27 (2013.01); A61P 35/00 (2018.01); C12N 5/0642 (2013.01); C12N 5/0647 (2013.01); G01N 33/57438 (2013.01); C12N 2500/32 (2013.01); C12N 2500/38 (2013.01); C12N 2501/02 (2013.01); C12N 2501/145 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2303 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2308 (2013.01); C12N 2501/2318 (2013.01); C12N 2501/25 (2013.01); C12N 2501/26 (2013.01); C12N 2501/305 (2013.01); C12N 2501/825 (2013.01); C12N 2506/11 (2013.01); C12N 2506/45 (2013.01)] 13 Claims
 
1. A method for treating a cancer comprising:
administering to a subject in need thereof a therapeutically effective amount of a composition comprising neutrophils derived from haematopoietic stem cells obtainable by a method, said method comprising:
a. admixing granulocytes obtained from a donor with cancer cells from a cancer cell line to form an admixture;
b. incubating said admixture;
c. measuring a percent (%) of cancer cells killed in the incubated admixture;
d. obtaining haematopoietic stem cells from a sample from the donor when the granulocytes kill at least 5% of the cancer cells in the incubated admixture; and
e. differentiating the haematopoietic stem cells from the donor to obtain the composition comprising neutrophils;
wherein the donor is allogeneic with the subject.